Cost/benefit analysis of pharmacologic hemostasis

Annals of Thoracic Surgery

Volumn 61, Issue 2 SUPPL., 1996, Pages

  Harmon, Donald E ^a  

^a OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; DESMOPRESSIN ACETATE; HEPARIN; PROTAMINE; TRANEXAMIC ACID;

BLEEDING; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG COST; HUMAN; PRIORITY JOURNAL; THORAX SURGERY;

EID: 0030044820     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(95)01079-3     Document Type: Conference Paper

References (18)

1. Bulpitt CJ, Fletcher AE. Measuring costs and financial benefits in randomized controlled trials. Am Heart J 1990;119(3 pt 2):766-70.
2. Goodnough LT, Soegiarso RW, Birkmeyer JD, Welch HG. Economic impact of inappropriate blood transfusions in coronary artery bypass graft surgery. Am J Med 1993;94: 509-14.
3. Despotis GJ, Santoro SA, Spitznagel E, et al. Prospective evaluation and clinical utility of on-site monitoring of coagulation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1994;107:271-9.
4. Despotis GJ, Santoro SA, Spitznagel E, et al. On-site prothrombin time, activated partial thromboplastin time, and platelet count: a comparison between whole blood and laboratory assays with coagulation factor analysis in patients presenting for cardiac surgery. Anesthesiology 1994;80: 338-51.
5. Lubarsky DA, Hahn C, Bennett DH, et al. The hospital cost (fiscal year 1991/1992) of a simple perioperative allogeneic red blood cell transfusion during elective surgery at Duke University. Anesth Analg 1994;79:629-37.
6. Gravlee GP. Interaction of systems: drugs and coagulation. American Society of Anesthesiologists Annual Refresher Course Lectures, San Francisco, CA, Oct 1994:512.
7. Cattaneo M, Moia M, Delle-Valle P, Castellana P, Mannucci PM, DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand's disease treated with cryoprecipitate: evidence for a mechanism of action independent of released von Willebrand factor. Blood 1989;74: 1972-5.
8. Kohler M, Hellstern P, Miyashita C, von Blohn G, Wenzel E. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). Thromb Haemost 1986:55:108-11.
9. Mongan PD, Hosking MP, The role of desmopressin acetate in patients undergoing coronary artery bypass surgery: a controlled clinical trial with thromboelastographic risk stratification. Anesthesiology 1992;77:38-46.
10. Mongan PD, Hosking MP. Desmopressin decreases blood loss and transfusion therapy after high-risk CPB procedures. Anesth Analg 1994;78:S292.
11. Horrow JC, Hlavacek J, Strong MD, et al. Prophylactic tranexamic acid decreases bleeding after cardiac operations. J Thorac Cardiovasc Surg 1990;99:70-4.
12. Karski JM, Teasdale SJ, Norman PH, Carroll JA, Weisel RD, Glynn MF. Prevention of postbypass bleeding with tranexamic acid and epsilon-aminocaproic acid. J Cardiothorac Vasc Anesth 1993;7:431-5.
13. Jordan DA, Delphin E, Rose E. Prophylactic EACA administration minimizes blood replacement therapy. Anesthesiology 1994;81:A92.
14. Van Iwaarden F, Bouma BN. Role of high molecular weight kininogen in contact activation. Semin Thromb Hemost 1987;13:15-24.
15. Heimark RL, Kurachi K, Fujikawa K, Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980;286:456-60.
16. Van Oeveren W, Jansen NJ, Bidstrup BP, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
17. Lemmer JH Jr, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency: a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994;107;543-51.
18. Embrey R. Coagulopathies: the magnitude of the problem. Presented at Coagulation Management of the Surgical Patient, American Society of Extracorporeal Technology, St Louis, MO, Sep 23-25, 1994.